Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$856M |
| 2 |
Meta Platforms (Facebook)
META
|
+$647M |
| 3 |
NVIDIA
NVDA
|
+$615M |
| 4 |
Berkshire Hathaway Class A
BRK.A
|
+$304M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$1.03B |
| 2 |
UnitedHealth
UNH
|
+$686M |
| 3 |
Tesla
TSLA
|
+$387M |
| 4 |
Abbott
ABT
|
+$380M |
| 5 |
Chevron
CVX
|
+$328M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.26% |
| 2 | Healthcare | 16.96% |
| 3 | Consumer Discretionary | 12.82% |
| 4 | Consumer Staples | 9.14% |
| 5 | Industrials | 9.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2951
Direxion Daily Semiconductor Bear 3X ETF
SOXS
$1.38B
| $433K | ﹤0.01% |
+22
| New | +$700K |
|
2952
Vanguard Extended Market ETF
VXF
$32.3B
| $432K | ﹤0.01% |
+2,900
| New | +$407K |
|
|
IRD
2953
Opus Genetics
IRD
$309M
| $432K | ﹤0.01% |
99,600
-90,369
| -48% | -$429K |
|
|
SFT
2954
DELISTED
Shift Technologies, Inc. Class A Common Stock
SFT
| $432K | ﹤0.01% |
198,972
-13,400
| -6% | -$22.2K |
|
2955
ReNew
RNW
$2.48B
| $430K | ﹤0.01% |
78,500
-64,500
| -45% | -$353K |
|
|
FPI
2956
Farmland Partners
FPI
$425M
| $429K | ﹤0.01% |
35,100
-60,802
| -63% | -$681K |
|
2957
VanEck Agribusiness ETF
MOO
$972M
| $428K | ﹤0.01% |
5,239
+939
| +22% | +$77.8K |
|
2958
Solitario Resources
XPL
$73.9M
| $428K | ﹤0.01% |
744,171
-4,000
| -0.5% | -$2.42K |
|
2959
Cytosorbents Corp
CTSO
$22.8M
| $427K | ﹤0.01% |
118,900
+300
| +0.3% | +$949 |
|
2960
Douglas Dynamics
PLOW
$967M
| $427K | ﹤0.01% |
14,300
-6,900
| -33% | -$203K |
|
|
BCLI
2961
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $426K | ﹤0.01% |
+13,787
| New | +$571K |
|
2962
Schwab US Mid-Cap ETF
SCHM
$15.3B
| $426K | ﹤0.01% |
+18,000
| New | +$406K |
|
2963
Hagerty
HGTY
$1.32B
| $425K | ﹤0.01% |
45,400
+4,458
| +11% | +$41.1K |
|
|
ACHL
2964
DELISTED
Achilles Therapeutics
ACHL
| $425K | ﹤0.01% |
449,733
+69,500
| +18% | +$66K |
|
2965
Rekor Systems
REKR
$97.6M
| $424K | ﹤0.01% |
+238,371
| New | +$332K |
|
|
RENT
2966
Rent the Runway
RENT
$122M
| $424K | ﹤0.01% |
10,715
-16,475
| -61% | -$811K |
|
|
DFAI
2967
Dimensional International Core Equity Market ETF
DFAI
$18B
| $423K | ﹤0.01% |
15,500
+1,800
| +13% | +$49.3K |
|
|
SNCR
2968
DELISTED
Synchronoss Technologies
SNCR
| $422K | ﹤0.01% |
50,481
+3,034
| +6% | +$25.6K |
|
2969
M-tron Industries
MPTI
$365M
| $421K | ﹤0.01% |
37,911
-13,002
| -26% | -$154K |
|
2970
ProShares Ultra S&P500
SSO
$8.51B
| $419K | ﹤0.01% |
+14,400
| New | +$377K |
|
2971
Aligos Therapeutics
ALGS
$42.3M
| $418K | ﹤0.01% |
17,222
-892
| -5% | -$23.9K |
|
|
DMRA
2972
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.9B
| $418K | ﹤0.01% |
6,634
+390
| +6% | +$21.2K |
|
2973
Bio-Rad Laboratories Class A
BIO
$9.66B
| $417K | ﹤0.01% |
1,100
-37,100
| -97% | -$15.1M |
|
2974
State Street SPDR S&P Dividend ETF
SDY
$22.2B
| $417K | ﹤0.01% |
3,400
+800
| +31% | +$97.7K |
|
2975
SES AI
SES
$227M
| $416K | ﹤0.01% |
+170,395
| New | +$330K |
|
Similar funds
Jim Simons's Q2 2023 Portfolio in Review
As of Q2 2023, Jim Simons held 4,468 positions worth $69.4B, down 7.9% from $75.4B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Jim Simons withdrew a net $8.1B in Q2 2023, closing 599 positions and reducing 1,691 holdings. Its most notable exit was UnitedHealth, an estimated $686M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Jim Simons opened a new position in Berkshire Hathaway Class A worth $316M.
- Jim Simons's largest Q2 2023 buy was Berkshire Hathaway Class A: 611 shares worth $316M.
- Jim Simons added most to Apple in Q2 2023, an estimated $856M increase.
- Jim Simons's biggest Q2 2023 reduction was Amazon, cutting an estimated $1.03B.
- Jim Simons fully exited UnitedHealth in Q2 2023, selling an estimated $686M.
- Jim Simons's ten largest holdings make up 12% of its $69.4B portfolio in Q2 2023.
- Jim Simons opened 541 new positions and closed 599 in Q2 2023.
- Jim Simons's portfolio value fell 7.9% quarter-over-quarter to $69.4B.
Based on Renaissance Technologies's 13F filing for Q2 2023, filed 11 Aug 2023.